Skip to main content
MENU
Subscribe
  • Sign Up Free
  • LOGIN
  • Subscribe
  • Topics
    • Alternatives
    • Artificial Intelligence
    • Consultants
    • Defined Contribution
    • ESG
    • ETFs
    • Face to Face
    • Hedge Funds
    • Industry Voices
    • Investing
    • Money Management
    • Partner Content
    • Pension Funds
    • Private Equity
    • Real Estate
    • Regulation
    • SECURE 2.0
    • Special Reports
    • Washington
    • White Papers
  • Rankings & Awards
    • 1,000 Largest Retirement Plans
    • Top-Performing Managers
    • Largest Money Managers
    • DC Money Managers
    • DC Record Keepers
    • Largest Hedge Fund Managers
    • World's Largest Retirement Funds
    • Best Places to Work in Money Management
    • Excellence & Innovation Awards
    • WPS Innovation Awards
    • Influential Women in Institutional Investing 2023
    • Eddy Awards
  • ETFs
    • Latest ETF News
    • Fund Screener
    • Education Center
    • Equities
    • Fixed Income
    • Commodities
    • Actively Managed
    • Alternatives
    • ESG Rated
  • ESG
    • Latest ESG News
    • The Institutional Investor’s Guide to ESG Investing
    • ESG Sustainability - Gaining Momentum
    • ESG Investing | Industry Brief
    • Innovation in ESG Investing
    • 2023 ESG Investing Conference
    • ESG Rated ETFs
    • Divestment Database
  • Defined Contribution
    • Latest DC News
    • The Plan Sponsor's Guide to Retirement Income
    • DC Money Manager Rankings
    • DC Record Keeper Rankings
    • Innovations in DC
    • DC Plan Design: Improving Participant Outcomes
    • 2023 Defined Contribution East Conference
  • Searches & Hires
    • Latest Searches & Hires News
    • Searches & Hires Database
    • RFPs
  • Research Center
    • The P&I Research Center
    • Earnings Tracker
    • Endowment Returns Tracker
    • Corporate Pension Contribution Tracker
    • Pension Fund Returns Tracker
    • Pension Risk Transfer Database
  • Careers
  • Events
    • View All Conferences
    • View All Webinars
  • Print
Breadcrumb
  1. Home
  2. INDUSTRY VOICES
December 17, 2021 06:30 AM

Commentary: Beyond COVID-19, health-care investing will be forever changed

Sheetal Prasad
  • Tweet
  • Share
  • Share
  • Email
  • More
    Sheetal Prasad
    Sheetal Prasad

    Full hospital beds, overwhelmed medical staff and a health-care system stretched to the brink — I saw the darkest days of the pandemic through the eyes of my husband, an emergency room physician who treated his first COVID-19 patient in early March 2020. As a research analyst and portfolio manager covering the health-care sector, I believed that prospects for quick relief were dim. It typically took a decade to discover a compound, go through clinical trials, get Food and Drug Administration approval and eventually get to market with a new drug. To my surprise, my husband received his first dose of the COVID vaccine a mere 10 months later.

    The rapid development of the COVID-19 vaccine is just one example of how the pandemic has impacted the health-care industry. In fact, in my 20 years as a health-care analyst, I have never seen a period like the last 18 months in terms of scientific innovation and business model evolution.

    This transformation couldn't come at a more opportune time as a new health-care crisis is looming. Currently, 10,000 Americans are aging into the Medicare system every day. By the year 2030, every baby boomer will be over the age of 65 and 1 out of every 5 Americans will be of retirement age. By 2035, according to the U.S. Census Bureau, there will be more elderly Americans than children under 18 for the first time in U.S. history. This "graying of America"— a trend similar in many other developed nations — could quickly place more demand on health care than there is supply.

    However, I have seen many developments over the past year that have convinced me the health-care sector will continue to grow, innovate and meet the higher demand. And just as COVID-19 accelerated the digital economy by five to 10 years, it has accelerated the scientific and medical economy as well.

    In fact, many innovative companies — especially in the biotech/pharma and life science and tools areas — have yet to unlock their full potential because they continue to focus their resources on COVID-19. Similarly, many medical device and health-care service companies face near-term challenges because elective procedures and doctor office visits have not recovered to their pre-COVID levels. As we come out of the pandemic, each of these industries, and more specifically many of these platforms, can focus on other unmet medical needs and therapeutic areas. And these markets — e.g., oncology, autoimmune, rare disease — are enormous. We see investment opportunities in innovative drug, device and service companies that are improving the ability to diagnose and treat disease, provide better access to care, lower costs and generate better clinical outcomes.

    Related Article
    Health-care plans adapt to reassure participants amid COVID-19
    Personalization via genetic advancement

    Why did some of those with COVID-19 have severe symptoms, while others appeared to be entirely healthy?

    The fact that not all people respond the same way to drugs and therapies has been one of the biggest mysteries of modern medicine. But the pandemic has significantly ramped up research and development to understand those unique differences — particularly at the single cell level, in which researchers can examine an individual's DNA, RNA and proteins for markers that might point toward more personalized treatment. This includes vaccines that can transform our own bodies into a production facility for antibodies — or, as many hope eventually, cancer-fighting agents.

    This approach to treating disease at the cellular level may cause some anxiety but, over time, the effectiveness of these cell- and gene-based therapies will likely make many patients more receptive and comfortable. As investors, we focus on 1) the biotech companies with these types of innovations and 2) life science and tools companies that make equipment and reagents used by researchers to better understand our own biology. We see significant potential in this area. The study of genetics, single cell analytics and proteomics can lead to breakthroughs in the treatments of infectious diseases, autoimmune disorders and cancer.

    Bloomberg

    Health workers at a drive through COVID-19 testing center set up in Malaysia.

    Small biotechs in medical supply chain

    While much attention over the past year has been focused on the big-name COVID-19 vaccine manufacturers such as Pfizer Inc., a whole supply chain of tools and service providers will help reinvent drug discovery and development.

    Many companies behind the creation of the COVID-19 vaccine were lesser-known upstarts, like Moderna Inc. and Germany-based BioNTech SE. This represents a new trend. Historically, most of the breakthroughs happened within large pharma companies. Today, much of the cutting-edge innovation is happening within small and emerging biotechs.

    How do these smaller players compete with the industry leaders? By outsourcing research and development, clinical trials and manufacturing to contract research organizations, or CROs, and contract development and manufacturing organizations, or CDMOs. These companies are not just low-value order takers — they are full partners in the process, providing valuable services at a time when speed and flexibility are of utmost importance.

    As investors, we are very interested in these CROs and CDMOs because they offer potential exposure to revolutionary treatments and drugs that meet growing needs in the health-care system. Specifically, we have looked for companies that have differentiated offerings in running clinical trials or specialize in manufacturing cell and gene therapy drugs.

    Bloomberg
    More accurate and convenient diagnostics

    Screenings for breast cancer and colon cancer fell sharply during the early days of the pandemic — down between 86% and 94% in March 2020, according to Epic Systems Corp., an electronic medical records vendor. We believe pent-up demand for screening tests will drive revenues for diagnostic companies higher in 2022, offering an opportunity for investors.

    We are also interested in companies that are pursuing the next generation of diagnostics. For example, new tools may soon allow for annual cancer screenings through a simple blood draw rather than timely, expensive and invasive procedures.


    Digital health care's rising acceptance

    Telemedicine and digital health apps rose to prominence during COVID-19 at a time when visiting the doctor in person was a frightening prospect. Despite an inevitable deceleration in app usage as the economy has reopened, these services are a critical part of our health-care future.

    When the world shut down due to the pandemic, patients were told to stay out of medical facilities. But even as doctors' offices are reopening, some people remain unenthusiastic about physical visits. Many patients today feel perfectly comfortable having intimate discussions over video with nurses and doctors, who can provide care and prescribe medications remotely.

    Sicker, chronically ill patients can now get better tools to manage their diabetes, hypertension and weight. Companies offer medical devices that connect through Bluetooth or the Internet of Things, allowing patients and their physicians to collect and evaluate health data (for example, their blood pressure or blood glucose levels). This data empowers patients to help manage their own health.

    The biggest impact of digital health care may be on mental health. The pandemic has increased behavioral therapy needs, and virtual therapy may actually be favored by patients who value privacy. Several virtual health apps use AI algorithms to better match providers with patients and, in some cases, help people do self-care.

    We have been looking closely at emerging growth companies that offer these services most effectively, which in some cases will be a hybrid of virtual, self-help and in-person approaches. There are several ways for investors to gain exposure to this theme, such as through companies that coordinate care, provide telemedicine and leverage wearable technology.

    Whatever the future holds, the models established during the pandemic provide a new foundation for solving the biggest threats to human health. COVID-19 placed many stresses on our society and communities, but it also showed that we can unleash the power of the global scientific community. The possibilities are endless.

    Sheetal Prasad is a managing director and small-cap core and midcap growth portfolio manager at Jennison Associates LLC, based in New York. This content represents the views of the author. It was submitted and edited under P&I guidelines but is not a product of P&I's editorial team.

    Related Articles
    Private equity’s health-care role draws spotlight
    Pandemic took greater toll on health-care sector plans – NEPC
    Recommended for You
    Photo of One Digital's Peter Kent
    Commentary: Emerging market debt deserves a seat at the table
    Photo of Mavik Capital Management's Vik Uppal
    Commentary: CRE opportunities still abound — but bargain hunting demands discipline of value investing
    Photo of Los Angeles Capital Management's Hal Reynolds and Sidharth Madan
    Commentary: What's next for high-quality growth stocks?
    Pension Risk Transfer: Derisking Trends and Considerations
    Sponsored Content: Pension Risk Transfer: Derisking Trends and Considerations
    Sponsored
    White Papers
    What a Fed pivot and ‘higher for longer’ mean for emerging markets
    A Guide to Home Equity Investments: The Untapped Real Estate Asset Class
    How to Modernize a School District Retirement Plan
    Q4 2023 Credit Outlook: Price Is What You Pay, Value Is What You Get
    There's More Than One Way to Be a Climate Investor
    Exploring the Commercial Application of Artificial Intelligence
    View More
    Sponsored Content
    Partner Content
    The Industrialization of ESG Investment
    For institutional investors, ETFs can make meeting liquidity needs easier
    Gold: the most effective commodity investment
    2021 Investment Outlook | Investing Beyond the Pandemic: A Reset for Portfolios
    Ten ways retirement plan professionals add value to plan sponsors
    Gold: an efficient hedge
    View More
    E-MAIL NEWSLETTERS

    Sign up and get the best of News delivered straight to your email inbox, free of charge. Choose your news – we will deliver.

    Subscribe Today
    October 23, 2023 page one

    Get access to the news, research and analysis of events affecting the retirement and institutional money management businesses from a worldwide network of reporters and editors.

    Subscribe
    Connect With Us
    • RSS
    • Twitter
    • Facebook
    • LinkedIn

    Our Mission

    To consistently deliver news, research and analysis to the executives who manage the flow of funds in the institutional investment market.

    About Us

    Main Office
    685 Third Avenue
    Tenth Floor
    New York, NY 10017-4036

    Chicago Office
    130 E. Randolph St.
    Suite 3200
    Chicago, IL 60601

    Contact Us

    Careers at Crain

    About Pensions & Investments

     

    Advertising
    • Media Kit
    • P&I Custom Content
    • P&I Careers | Post a Job
    • Reprints & Permissions
    Resources
    • Subscribe
    • Newsletters
    • FAQ
    • P&I Research Center
    • Site map
    • Staff Directory
    Legal
    • Privacy Policy
    • Terms and Conditions
    • Privacy Request
    Pensions & Investments
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • Topics
      • Alternatives
      • Artificial Intelligence
      • Consultants
      • Defined Contribution
      • ESG
      • ETFs
      • Face to Face
      • Hedge Funds
      • Industry Voices
      • Investing
      • Money Management
      • Partner Content
      • Pension Funds
      • Private Equity
      • Real Estate
      • Regulation
      • SECURE 2.0
      • Special Reports
      • Washington
      • White Papers
    • Rankings & Awards
      • 1,000 Largest Retirement Plans
      • Top-Performing Managers
      • Largest Money Managers
      • DC Money Managers
      • DC Record Keepers
      • Largest Hedge Fund Managers
      • World's Largest Retirement Funds
      • Best Places to Work in Money Management
      • Excellence & Innovation Awards
      • WPS Innovation Awards
      • Influential Women in Institutional Investing 2023
      • Eddy Awards
    • ETFs
      • Latest ETF News
      • Fund Screener
      • Education Center
      • Equities
      • Fixed Income
      • Commodities
      • Actively Managed
      • Alternatives
      • ESG Rated
    • ESG
      • Latest ESG News
      • The Institutional Investor’s Guide to ESG Investing
      • ESG Sustainability - Gaining Momentum
      • ESG Investing | Industry Brief
      • Innovation in ESG Investing
      • 2023 ESG Investing Conference
      • ESG Rated ETFs
      • Divestment Database
    • Defined Contribution
      • Latest DC News
      • The Plan Sponsor's Guide to Retirement Income
      • DC Money Manager Rankings
      • DC Record Keeper Rankings
      • Innovations in DC
      • DC Plan Design: Improving Participant Outcomes
      • 2023 Defined Contribution East Conference
    • Searches & Hires
      • Latest Searches & Hires News
      • Searches & Hires Database
      • RFPs
    • Research Center
      • The P&I Research Center
      • Earnings Tracker
      • Endowment Returns Tracker
      • Corporate Pension Contribution Tracker
      • Pension Fund Returns Tracker
      • Pension Risk Transfer Database
    • Careers
    • Events
      • View All Conferences
      • View All Webinars
    • Print